BAFNAPH

Bafna Pharmaceuticals Limited

Pharmaceutical formulations company with domestic manufacturing and sales

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

bafnapharma.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹461.35
Market cap
1,091 Cr
Stock P/E
140.2
P/B
11.37
ROE (FY20)
-46.2%
ROCE (FY20)
-46.1%
Operating margin (FY20)
-4.8%
Debt / equity (FY20)
0.00
OCF / EBITDA (FY26)
96.4%
OCF / EBITDA (3Y)
122.9%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Bafna Pharmaceuticals makes finished-dose medicines (tablets and capsules) at its plant at Red Hills, Chennai, and sells them in India and to export markets through distributors, government tenders and agents.

Company snapshot

90thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓123% of operating profit came in as cash over the last three years — profits are backed by real cash.
Concerns
  • ✗Net margin is negative — the company is spending more than it earns right now.
3 more signals from the filings.Sign in free to see them all

Statement tables · Standalone

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales41 Cr28 Cr41 Cr33 Cr40 Cr33 Cr39 Cr35 Cr35 Cr38 Cr42 Cr27 Cr
Operating expenses (approx.)37 Cr31 Cr39 Cr32 Cr37 Cr30 Cr36 Cr30 Cr31 Cr35 Cr39 Cr26 Cr
EBITDA4 Cr-2 Cr3 Cr1 Cr4 Cr3 Cr3 Cr5 Cr4 Cr3 Cr4 Cr0.88 Cr
OPM %9.8%-7.3%7.0%3.6%9.4%9.2%8.0%14.6%12.1%8.0%8.4%3.3%
Other income0.16 Cr0.98 Cr0.52 Cr0.51 Cr1 Cr0.19 Cr1 Cr0.60 Cr1 Cr1 Cr2 Cr2 Cr
Interest0.44 Cr0.58 Cr0.68 Cr0.65 Cr0.62 Cr0.64 Cr0.82 Cr0.91 Cr0.86 Cr0.86 Cr1 Cr0.94 Cr
Depreciation1 Cr1 Cr1 Cr1 Cr2 Cr2 Cr0.22 Cr1 Cr1 Cr2 Cr2 Cr2 Cr
Profit before tax2 Cr-3 Cr1 Cr-0.72 Cr3 Cr0.95 Cr1 Cr3 Cr3 Cr2 Cr3 Cr0.08 Cr
Tax %0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%-4.9%0.0%
Net profit2 Cr-3 Cr1 Cr-0.72 Cr3 Cr0.95 Cr1 Cr3 Cr3 Cr2 Cr3 Cr0.08 Cr
EPS (₹)₹1.05₹-1.24₹0.62₹-0.31₹1.11₹0.40₹0.55₹1.43₹1.32₹0.78₹1.16₹0.03

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales65 Cr47 Cr44 Cr42 Cr71 Cr85 Cr115 Cr152 Cr146 Cr151 CrSign in free for the trailing twelve months
Operating expenses (approx.)70 Cr82 Cr57 Cr41 Cr61 Cr74 Cr100 Cr141 Cr135 Cr135 CrSign in free for the trailing twelve months
EBITDA-5 Cr-35 Cr-13 Cr1 Cr10 Cr11 Cr16 Cr11 Cr11 Cr16 CrSign in free for the trailing twelve months
OPM %-8.0%-74.4%-30.0%2.9%14.5%13.5%13.6%7.3%7.7%10.6%Sign in free for the trailing twelve months
Other income1 Cr31 Cr0.39 Cr0.26 Cr0.75 Cr2 Cr3 Cr4 Cr3 Cr5 CrSign in free for the trailing twelve months
Interest11 Cr7 Cr2 Cr0.10 Cr0.74 Cr0.79 Cr2 Cr2 Cr3 Cr4 CrSign in free for the trailing twelve months
Depreciation4 Cr4 Cr3 Cr3 Cr4 Cr5 Cr5 Cr5 Cr5 Cr6 CrSign in free for the trailing twelve months
Profit before tax-19 Cr-14 Cr-18 Cr-25 Cr6 Cr5 Cr12 Cr7 Cr4 Cr11 CrSign in free for the trailing twelve months
Tax %4.3%-15.2%-8.2%0.0%0.0%0.0%2.4%0.0%0.0%-1.2%Sign in free for the trailing twelve months
Net profit-18 Cr-16 Cr-20 Cr-25 Cr6 Cr5 Cr11 Cr7 Cr4 Cr11 CrSign in free for the trailing twelve months
EPS (₹)₹-9.90₹-6.95₹-8.34₹-106.54₹2.46₹2.17₹4.86₹3.11₹1.76₹4.69Sign in free for the trailing twelve months
Dividend payout %————0.0%0.0%0.0%0.0%0.0%0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital—24 Cr24 Cr2 Cr24 Cr24 Cr24 Cr24 Cr24 Cr24 Cr
Reserves—17 Cr-3 Cr51 Cr33 Cr39 Cr50 Cr57 Cr61 Cr72 Cr
Borrowings—47 Cr46 Cr—3 Cr8 Cr23 Cr24 Cr28 Cr37 Cr
Other liabilities—40 Cr54 Cr—27 Cr19 Cr33 Cr42 Cr40 Cr42 Cr
Total liabilities—128 Cr121 Cr—86 Cr90 Cr130 Cr148 Cr153 Cr176 Cr
Fixed assets (net)—40 Cr37 Cr—36 Cr39 Cr40 Cr40 Cr59 Cr82 Cr
CWIP————0.83 Cr—2 Cr10 Cr7 Cr3 Cr
Investments—1 Cr1 Cr———0 Cr0 Cr0.0005 Cr0.0005 Cr
Loans & advances——————0.05 Cr0.08 Cr0.02 Cr0.08 Cr
Inventories—11 Cr9 Cr—15 Cr20 Cr22 Cr30 Cr28 Cr29 Cr
Trade receivables—24 Cr25 Cr—10 Cr15 Cr41 Cr45 Cr40 Cr44 Cr
Cash & bank—3 Cr3 Cr—2 Cr0.17 Cr8 Cr1 Cr3 Cr2 Cr
Other assets—48 Cr45 Cr—23 Cr16 Cr17 Cr20 Cr15 Cr16 Cr
Total assets—128 Cr121 Cr—86 Cr90 Cr130 Cr148 Cr153 Cr176 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity20 Cr-7 Cr-1 Cr—-9 Cr7 Cr5 Cr9 Cr22 Cr15 Cr
Cash from investing-14 Cr38 Cr4 Cr—6 Cr-5 Cr-7 Cr-15 Cr-21 Cr-22 Cr
Cash from financing-5 Cr-31 Cr-2 Cr—12 Cr-4 Cr10 Cr-0.85 Cr1 Cr6 Cr
Net cash flow-0.04 Cr0.05 Cr0.0021 Cr—10 Cr-2 Cr8 Cr-6 Cr2 Cr-1 Cr
Free cash flow (OCF − Capex)20 Cr-7 Cr-1 Cr—-9 Cr-1 Cr-3 Cr-6 Cr0.28 Cr-10 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020
ROCE %—-9.3%—-46.1%
ROE %—-45.5%—-46.2%
Debtor days—187——
Inventory days—145——
Days payable—388——
Cash conversion cycle—-56——
Debt / equity—1.252.450.00
Current ratio—0.810.68—
Net debt / EBITDA———0.00
Bafna Pharmaceuticals Limited (BAFNAPH) Financials | BullKarma